Abstract
The Neuropilin receptors are increasingly recognized as receptors for vascular endothelial growth factors like VEGF-A and VEGF-C as well as other important growth factors like HGF and FGF in human vasculature and in tumor cells. More and more studies show an important role of Neuropilin in cancer biology suggesting that these transmembrane proteins might be an emerging target for new therapies in different subsets of cancer. Interestingly, blocking the adaptor protein GIPC1/Synectin that interacts with Neuropilin might be another interesting avenue for therapy. This review summarizes unfolding scientific data on these receptors and its interacting protein GIPC1/Synectin as molecular targets for therapy in pancreatic ductal adenocarcinoma.
Keywords: GIPC1, neuropilin-1, neuropilin-2, pancreatic cancer, synectin, targeted therapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Volume: 11 Issue: 5
Author(s): Michael H. Muders
Affiliation:
Keywords: GIPC1, neuropilin-1, neuropilin-2, pancreatic cancer, synectin, targeted therapy
Abstract: The Neuropilin receptors are increasingly recognized as receptors for vascular endothelial growth factors like VEGF-A and VEGF-C as well as other important growth factors like HGF and FGF in human vasculature and in tumor cells. More and more studies show an important role of Neuropilin in cancer biology suggesting that these transmembrane proteins might be an emerging target for new therapies in different subsets of cancer. Interestingly, blocking the adaptor protein GIPC1/Synectin that interacts with Neuropilin might be another interesting avenue for therapy. This review summarizes unfolding scientific data on these receptors and its interacting protein GIPC1/Synectin as molecular targets for therapy in pancreatic ductal adenocarcinoma.
Export Options
About this article
Cite this article as:
H. Muders Michael, Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/187152011795677481
DOI https://dx.doi.org/10.2174/187152011795677481 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Amniotic Fluid Stem Cells as an Attractive Tool for Clinical Applications
Current Stem Cell Research & Therapy Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Transferrin Coupled Liposomes for Enhanced Brain Delivery of Doxorubicin
Vascular Disease Prevention (Discontinued) Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Natural Products with Antiangiogenic and Antivasculogenic Mimicry Activity
Mini-Reviews in Medicinal Chemistry Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Current Drug Metabolism From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers
Current Medicinal Chemistry Cytosine Methyltransferases as Tumor Markers
Current Genomics Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas
Current Gene Therapy Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Radiopharmaceutical Chemistry with Iodine-124: A Non-Standard Radiohalogen for Positron Emission Tomography
Medicinal Chemistry Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Current Topics in Medicinal Chemistry CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets